Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives

Int J Colorectal Dis. 2004 Sep;19(5):401-13. doi: 10.1007/s00384-003-0563-3. Epub 2004 Jan 24.

Abstract

Background: Pancreatic ductal adenocarcinoma has an extremely poor prognosis. To improve the prognosis, novel molecular markers and targets for earlier diagnosis and adjuvant and/or neoadjuvant treatment need to be identified. One of the key techniques that has been developed to achieve this goal is DNA microarray profiling, which is used to identify the mechanisms of deregulated molecular functions in pancreatic carcinoma cells.

Objective: As several studies using microarrays have already been published, this review attempts to compare published data and crossvalidate the results. In addition, the applied techniques are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Pancreatic Ductal / genetics*
  • Carcinoma, Pancreatic Ductal / pathology*
  • Carcinoma, Pancreatic Ductal / therapy
  • DNA, Neoplasm / analysis
  • Gene Expression Profiling*
  • Humans
  • Neoadjuvant Therapy
  • Oligonucleotide Array Sequence Analysis*
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / therapy
  • Prognosis

Substances

  • DNA, Neoplasm